The recording of this insightful webinar discussing the Novelties in the early detection, treatment and lifestyle interventions for Alzheimer’s disease is now available on the AD/PD™ Education Portal.
Learning Objectives:
- To introduce the webinar topics and objectives and assess participants’ initial knowledge, attitudes and practices related to Alzheimer’s disease.
- To delve into the latest research on Alzheimer’s disease, focusing on its pathophysiology and the barriers to early detection.
- To explore the latest diagnostic tools for Alzheimer’s disease, focusing on both qualitative and quantitative methods and the emerging role of biomarkers.
- To review the latest developments in the treatment of Alzheimer’s disease, including drug development and non-pharmacological interventions.
Topics that will be covered:
- Understanding Alzheimer’s disease biological cascade.
- Alzheimer’s disease: recent tools for early diagnosis.
- Latest treatments and lifestyle interventions for Alzheimer’s disease.
Faculty:
Prof. Dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He was appointed as Professor of Cognitive Neurology in 2000 and founded the Alzheimer Center at Amsterdam University Medical Centers in that same year, which he directed until 2022. Currently he is partner at EQT group and heads the Dementia Fund at EQT Life Sciences, that he started in 2020. In his current job, he leads the Investment Team of the Fund and sits on the board of three portfolio companies: Aviado Bio, NOBI, AstronautX and is special advisor to New Amsterdam Pharma, the first company the team invested in, now listed at the NY Stock Exchange.
Dr. Marit Ruitenberg, PhD is an Assistant Professor at the Health, Medical and Neuropsychology section at Leiden University, the Netherlands. Her research focuses on the cognitive and neural mechanisms underlying sensorimotor function across the lifespan, both in health and neuro(psycho)logical disorders. Using a combination of behavioral and neuroimaging methods (fMRI, fcMRI), she aims to contribute towards a better understanding of how our brain controls movement, and how such control changes due to aging or disorders such as Parkinson’s disease, Alzheimer’s disease, or depression.
Dr. Suzanne Hendrix graduated from Boston University with a Ph.D. in mathematics. Dr. Hendrix has worked as a clinical trial statistician and has now accumulated over 30 years of experience with time spent at CROs and pharmaceutical companies, including projects across many disease areas. Since becoming CEO of Pentara in 2008, Dr. Hendrix has maintained a central focus on analysis of clinical trials for degenerative diseases, especially Alzheimer’s disease (AD). Suzanne has first authored or co-authored over 150 peer-reviewed publications related to both clinical trial results and statistical approaches for clinical trials, many of which include significant contributions to statistical methodology for Alzheimer’s disease. Dr. Hendrix also played an important role in the development of ADCOMS, an AD composite score to measure cognitive function in individuals with mild cognitive impairment due to AD.
James E. Galvin, M.D., M.P.H. is Professor of Neurology and Psychiatry & Behavioral Sciences, and the Alexandria and Bernard Schoninger Endowed Chair for Memory Disorders at the University of Miami Miller School of Medicine. He is Division Chief for Cognitive Neurology, Founding Director of the Comprehensive Center for Brain Health, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence, and Principal Investigator for the Native Alzheimer’s Disease Resource Center in Minority Aging Research. Dr. Galvin has authored over 390 scientific publications (h-index=73). Dr. Galvin has received over $120 Million in research funding from the National Institutes of Health, Disease Associations, Private and Family Foundations.
This webinar is supported by an educational grant from Novo Nordisk A/S.
***IMPORTANT***
Please note that this Educational Activity is not available to participants from the United States and the United Kingdom due to regional restrictions.
We appreciate your understanding, and we apologize for the inconvenience.